Alnylam reports new 12-month interim data from the envision phase 3 study of givosiran in acute hepatic porphyria

Alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced the presentation of new data from the open-label

ALNY Ratings Summary

ALNY Quant Ranking